GenSight Biologics S.A.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a GSGTF research report →
Price Chart
About the company
GenSight Biologics S. A. is a clinical-stage biotechnology firm dedicated to pioneering, advancing, and bringing to market treatments for serious eye and central nervous system disorders, specifically those linked to mitochondrial dysfunction and neurodegeneration.
- CEO
- Laurence Rodriguez
- IPO
- 2018
- Employees
- 13
- HQ
- Paris, IF, FR
Get TickerSpark's AI analysis on GSGTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $13.04M
- P/E
- -1.10
- Fwd P/E
- 0.06
- PEG
- -0.02
- P/S
- -10.41
- P/B
- -0.53
- EV/EBITDA
- -1.84
- Div Yield
- 0.00%
- Gross Margin
- 3.74%
- Op Margin
- 1096.34%
- Net Margin
- 1220.37%
- ROE
- 52.39%
- ROIC
- 738.45%
Latest fiscal year · YoY change
- Revenue
- $999.63-99.9%
- Gross Profit
- $1.00K-99.9%
- Op Income
- $-11,700,615
- Net Income
- $-12,031,491+14.1%
- EPS
- $-0.08+52.2%
- OCF Growth
- +29.1%
- FCF Growth
- +29.1%
- 52W High
- $0.48
- 52W Low
- $0.08
- 50D MA
- $0.09
- 200D MA
- $0.15
- Beta
- 0.73
- RSI (14)
- 40
- Avg Volume
- 6
No earnings-call transcripts are available for GSGTF yet.
- Free Float
- 103.4%
- Shares Outstanding
- 163.00M
- Float Shares
- 168.52M
Our GSGTF coverage
Recent articles, reports, and earnings notes.
No research on GSGTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate GSGTF report →Gensight Biologics and the 15-20 National Hospital Announce NEJM Publication on GS030 Phase 1/2 Trial Results in Late-Stage Retinitis Pigmentosa
businesswire.com · Oct 8
GenSight Biologics Announces a Successful €1.0 Million Fundraising Supported by Existing Shareholders
businesswire.com · Oct 8
GenSight Biologics Reports Cash Position as of September 30, 2026
businesswire.com · Oct 7
GenSight Biologics Reports Interim Financial Results for the First Half of 2026 and Provides Business Updates
businesswire.com · Sep 29
GenSight Biologics Provides September 2026 Business Updates
businesswire.com · Sep 8
Financial Analysis: Pyxis Oncology (NASDAQ:PYXS) and GenSight Biologics (OTCMKTS:GSGTF)
defenseworld.net · Aug 13
GenSight Biologics Reports Cash Position as of June 30, 2026, and Provides Business Updates
businesswire.com · Jul 8
GenSight Biologics Announces the Results of its Combined General Meeting of May 19, 2026
businesswire.com · May 20
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.